US and UK Establish Duty-Free Deal on Drugs.
The UK and US have signed a key commercial pact that will maintain no duties on UK drug exports being sold in the American market.
Key Provisions of the Deal
As part of the deal, the UK has agreed to increase funding on drugs through the public health system. This pledge guarantees that duties on these crucial goods will be held at zero for a period of 36 months.
This deal comes after recent statements to hike import taxes on branded drug imports, with figures floated up to one hundred percent.
"This deal between the UK bolsters the international landscape for innovative medicines and establishes much-needed equity to transatlantic drug exports," an announcement said.
Trade Impact
Drugs represent one of the Britain's most significant export categories to the United States, which is by far the biggest market for leading UK drugmakers.
Statistics indicate that in the year leading up to September, the UK exported pharmaceutical products totaling billions to the US. This figure made up a significant portion of total UK exports in that period.
"This guarantee protects employment, stimulates capital expenditure and facilitates the UK to emerge as a worldwide center for life sciences," a minister stated.
Specific UK Commitments
The agreement includes several specific changes from the British government:
- Revised Affordability Limit: The UK will raise the affordability limit at which it considers new treatments to be too expensive by a quarter.
- Higher Drug Budget: There is a target to increase overall health service expenditure on medicines from 0.3 percent of Gross Domestic Product to 0.6% over the following ten-year period.
- Refund Ceiling: The amount drug companies must return to the NHS to stay within budget will be capped at fifteen percent. Previously, repayments exceeded 20%.
Industry Background
The pact takes place against a protracted tension between the sector and the UK government over spending levels and NHS adoption.
This friction were intensified by arguments that American patients were paying a premium for the equivalent treatments than people in the UK and Europe.
Over the last 18 months, several large pharmaceutical investments in the UK have been paused or abandoned, while major expansions have been announced toward projects in the United States.
The Science Minister acknowledged that the NHS needed to invest a greater share on drugs, noting that its spending on drugs had shrunk as a proportion of its total funding over the last ten years.
